Participants receiving the potent and highly selective BTK inhibitor fenebrutinib maintained low disease activity in the OLE of the FENopta study.
The post MS Activity Remains Low on Long-Term Fenebrutinib first appeared on Physician’s Weekly.
MS Activity Remains Low on Long-Term Fenebrutinib
Leave a Reply
We bring you the best Premium WordPress Themes that perfect for news, magazine, personal blog, etc. Check our landing page for details.